Adicet Bio (NASDAQ:ACET – Get Rating) issued its quarterly earnings data on Thursday. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.28, MarketWatch Earnings reports.
NASDAQ:ACET opened at $11.83 on Friday. Adicet Bio has a 12-month low of $6.25 and a 12-month high of $21.17. The stock’s fifty day simple moving average is $15.74 and its 200-day simple moving average is $13.82.
In other news, SVP Francesco Galimi sold 7,979 shares of the business’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $21.00, for a total value of $167,559.00. Following the completion of the transaction, the senior vice president now owns 59,917 shares of the company’s stock, valued at approximately $1,258,257. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Aya Jakobovits sold 4,000 shares of the firm’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $14.83, for a total value of $59,320.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 19,600 shares of company stock valued at $386,920. 33.90% of the stock is owned by insiders.
ACET has been the topic of several analyst reports. JMP Securities lowered their price target on Adicet Bio from $30.00 to $21.00 and set a “market outperform” rating on the stock in a report on Thursday, March 17th. Sumitomo Mitsui Financial Group started coverage on Adicet Bio in a research note on Thursday, March 31st. They set an “outperform” rating and a $28.00 target price for the company. Jefferies Financial Group assumed coverage on Adicet Bio in a research report on Friday, March 4th. They issued a “buy” rating and a $27.00 price target on the stock. Truist Financial started coverage on shares of Adicet Bio in a research report on Tuesday, March 8th. They set a “buy” rating and a $30.00 price objective for the company. Finally, StockNews.com assumed coverage on Adicet Bio in a research report on Thursday, March 31st. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $27.58.
About Adicet Bio (Get Rating)
Adicet Bio, Inc, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
- Get a free copy of the StockNews.com research report on Adicet Bio (ACET)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.